Friedrich-Ebert-Krankenhaus Neumünster
Welcome,         Profile    Billing    Logout  
 1 Trial 
45 Trials

   

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Pace, Andrea
ACTION, NCT05580562: ONC201 in H3 K27M-mutant Diffuse Glioma Following Radiotherapy (the Study)

Calendar Jan 2026 - Dec 2026: Final data from ACTION trial for newly diagnosed H3 K27M-mutant diffuse glioma
Jan 2025 - Mar 2025: Interim data from ACTION trial for newly diagnosed H3 K27M-mutant diffuse glioma
Recruiting
3
450
Europe, Canada, Japan, US, RoW
Dordaviprone (ONC201), Dordaviprone (ONC201) + Placebo, Placebo
Chimerix
H3 K27M, Glioma
08/26
08/26
RACTAC, NCT04224441: Repurposing Chlorpromazine in the Treatment of Glioblastoma

Recruiting
2
41
Europe
Chlorpromazine Pill, Temozolomide
Marco G Paggi, MD, PhD, Regina Elena Cancer Institute, Carlo Besta Neurological Institute, Istituto Oncologico Veneto IRCCS
Glioblastoma Multiforme, MGMT-Unmethylated Glioblastoma
06/22
12/22
NCT04762069 / 2021-003659-40: A Study of Berubicin in Adult Subjects With Recurrent Glioblastoma Multiforme

Hourglass Jan 2023 - Jun 2023 : Data from trial for glioblastoma
Hourglass Jul 2022 - Dec 2022 : Interim analysis data from trial for glioblastoma in adults
Active, not recruiting
2
210
Europe, US
Berubicin, Berubicin Hydrochloride, Lomustine, Lomustine Capsules, CCNU, CeeNU, Gleostine
CNS Pharmaceuticals, Inc., Worldwide Clinical Trials
Glioblastoma Multiforme, Adult
12/24
03/25
eCAN, NCT06007001: Telerehabilitation and Tele-psychological Support in Cancer Patients JA

Recruiting
N/A
354
Europe, RoW
Telemedicine
Sciensano, European Commission
Cancer
09/24
09/24
SILMET, NCT05689619: SILibinin in NSCLC and BC Patients With Single Brain METastasis

Recruiting
N/A
70
Europe
Silibinin, Sillbrain, Placebo
Azienda Ospedaliera Città della Salute e della Scienza di Torino
Brain Metastases, Adult, Non Small Cell Lung Cancer, Breast Cancer
09/25
09/27
Siegler, Gabriele
RAMTAS, NCT03520946 / 2017-004162-99: RAMucirumab in Combination Wth TAS102 vs. TAS102 Alone in Chemotherapy Refractory Metastatic Colorectal Cancer Patients

Completed
3
430
Europe
Ramucirumab, TAS 102
Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest, Eli Lilly and Company, Trium Analysis Online GmbH
Colorectal Cancer
07/24
07/24
NCT05008809: Post-resection/Ablation Chemotherapy in Patients With Metastatic Colorectal Cancer (FIRE-9 - PORT / AIO-KRK-0418)

Recruiting
3
507
Europe
mFOLFOX6, Folinic acid, Oxaliplatin, 5-fluorouracil (FU), mFOLFOXIRI, Folinic acid, Oxaliplatin, 5-FU, Irinotecan, FOLFIRI, Folinic acid, 5-FU, CAPOX, Capecitaine, Oxaliplatin
Dominik Paul Modest, German Research Foundation, Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest
Colorectal Cancer
11/27
11/30
NeoART, NCT06731803: Platform Trial Evaluating Treatment of Neoadjuvant Trastuzumab-deruxtecan Containing Combination Therapies for HER2+, Resectable Esophagogastric Adenocarcinoma

Recruiting
1/2
36
Europe
Trastuzumab deruxtecan + 5FU/LV, Trastuzumab deruxtecan + FLO
Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest, Daiichi Sankyo
Esophagogastric Adenocarcinoma
12/27
12/27
Götze, Thorsten
COMPASS, NCT03164980: QoL-Comparison Between Trabectedin/PLD and Pt-based Therapy in Patients With Pt-sensitive Recurrent Ovarian Cancer

Terminated
4
89
Europe
Trabectidin (Yondelis)
North Eastern German Society of Gynaecological Oncology, Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest, PharmaMar
Quality of Life, Ovarian Cancer, Recurrent Ovarian Carcinoma
08/23
08/23
NCT04817189 / 2019-004686-41: Oral Akynzeo® Vs Standard of Care in Preventing CINV in High-risk MEC Patients (MyRisk)

Completed
4
414
Europe, RoW
NEPA (300mg netupitant/0.5mg palonosetron), Akynzeo® capsules, Granisetron, 2 mg (oral) or 1 mg (IV) OR Palonosetron, 0.5 mg (oral), 0.25mg (IV) OR Ondansetron, 16 mg (oral) or 8 mg (IV) OR Dolasetron 100 mg (oral) OR Tropisetron 5 mg (oral or IV), 5-HT3 RA, Dexamethasone, 8 mg (oral) or equivalent IV dose, corticosteroid
Helsinn Healthcare SA
Chemotherapy-induced Nausea and Vomiting
07/24
07/24
ABC-HCC, NCT04803994 / 2020-004210-35: The Trial: Atezolizumab Plus Bevacizumab vs. Transarterial Chemoembolization (TACE) in Intermediate-stage HepatoCellular Carcinoma

Recruiting
3
434
Europe, Japan
Atezolizumab, Tecentriq, Bevacizumab, Avastin, TACE, transarterial chemoembolization
Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest, F. Hoffmann-La Roche Ltd
Hepatocellular Carcinoma
07/27
07/27
NCT03948789: Phase III Study of MR-Guided Focused Ultrasound Surgery for the Treatment of Uterine Fibroids Compared to Myomectomy

Active, not recruiting
3
127
Europe
Magnetic Resonance Imaging-controlled high-focussed ultrasound therapy, Myomectomy (laparoscopic or open surgical)
Krankenhaus Nordwest
Uterine Fibroids
09/25
10/25
NCT04246684: Short RT Versus RCT,Followed by Chemo.and Organ Preservation for Interm and High-risk Rectal Cancer Patients

Active, not recruiting
3
702
Europe
Oxaliplatin, 85 mg/m2, Control arm, 5FU; 2400 mg/m2, 5-FU, control arm, 5FU, 250 mg/m2, Experimental arm: 5-FU, 5FU, 2400 mg/m2, experimental arm, Oxaliplatin 50 mg/m2, Experimental arm, Folinic Acid, 400 mg/m2, Folinic Acid, Radiotherapy control, 5x5 Gy: 25 Gy, Capecitabine, 1000 mg/m2, Capecitabine, Oxaliplatin 85 mg/m2, radiotherapy experimental, 30 x 1,8 Gy: 54 Gy, Capecitabine, 825 mg/m2, Oxaliplatin, 130 mg/m2, Oxaliplatin
Prof. Dr. med. Claus Rödel
Rectal Cancer Stage III
09/23
09/28
PREVENT, NCT04447352 / 2017-003832-35: HIPEC + FLOT vs. FLOT Alone in Patients With Gastric Cancer and GEJ

Recruiting
3
200
Europe
5-Fluorouracil, 5-FU, Leucovorin, Calciumfolinat, Oxaliplatin, Docetaxel, Cisplatin
Krankenhaus Nordwest, Deutsche Krebshilfe e.V., Bonn (Germany)
Gastric Cancer, Gastroesophageal Junction Adenocarcinoma
11/26
05/27
NCT05008809: Post-resection/Ablation Chemotherapy in Patients With Metastatic Colorectal Cancer (FIRE-9 - PORT / AIO-KRK-0418)

Recruiting
3
507
Europe
mFOLFOX6, Folinic acid, Oxaliplatin, 5-fluorouracil (FU), mFOLFOXIRI, Folinic acid, Oxaliplatin, 5-FU, Irinotecan, FOLFIRI, Folinic acid, 5-FU, CAPOX, Capecitaine, Oxaliplatin
Dominik Paul Modest, German Research Foundation, Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest
Colorectal Cancer
11/27
11/30
CaboRISE, NCT04522908: Dose Escalation Study of Cabozantinib for Advanced HCC Patients with Preserved Liver Function

Completed
2
40
Europe
Cabozantinib Oral Tablet, CABOMETYX
Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest, Johann Wolfgang Goethe University Hospital, Prof. Dr. med. Trojan
Hepatocellular Carcinoma (HCC), Second Line Treatment
10/24
10/24
PRESTO, NCT05713838: Organ Preservation With Durvalumab-based Immunotherapy in Combination With Chemoradiation as Definitive Therapy for Early Stage Esophageal Adenocarcinoma With Indication for Radical Surgery

Recruiting
2
32
Europe
Durvalumab, IMFINZI, FLOT, mFOLFOX-6, Radiotherapy
Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest
Esophagus Adenocarcinoma
12/25
12/28
ADJUBIL, NCT05239169: Immunotherapy With Durva and Treme With or Without Capecitabine in Adjuvant Treatment for Biliary Tract Cancer

Active, not recruiting
2
40
Europe
Durvalumab, Tremelimumab, Capecitabine
Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest
Biliary Tract Cancer (CCA), Intrahepatic Cholangiocarcinoma, Hilar Cholangiocarcinoma, Distal Cholangiocarcinoma, Gall Bladder Carcinoma
12/24
06/25
NCT06680622: Bemarituzumab in FGFR2b+ Patients with Advanced or Metastatic Adenocarcinoma of the Stomach or Gastroesophageal Junction, Who Failed At Least One Prior Line of Palliative Chemotherapy

Recruiting
2
126
Europe
bemarituzumab, paclitaxel, ramucirumab, bemarituzumab, irinotecan, bemarituzumab, trifluridine/tipiracil
Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest, Amgen, Johannes Gutenberg University Mainz, Technical University of Munich
Metastatic Gastro-esophageal Adenocarcinoma
09/27
03/28
NCT06856837: - IKF/AIO-QUINTIS - Evaluating Fruquintinib in Combination With Tislelizumab in Microsatellite Stable / Proficient Mismatch Repair (MSS/pMMR) Metastatic Colorectal Cancer Without Active Liver Metastases

Not yet recruiting
2
140
Europe
Fruquintinib, Fruzaqla, Tislelizumab, Tevimbra, Trifluridine/tipiracil, Lonsurf, Bevacizumab, Avastin
Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest
Metastatic Colorectal Cancer
12/29
12/29
FUTURE, NCT06722183: Futibatinib in Combination With (Chemo)Immunotherapy in Colorectal Cancer and Other Solid Tumor Entities

Not yet recruiting
2
33
Europe
Futibatinib orally administered, Tislelizumab (i.v. 200mg)
Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest, Universitätsmedizin Mainz, I. Medizinische Klinik, Forschungslabor Prof. Möhler
Colorectal Cancer
09/27
09/27
FORTE, NCT05503797 / 2022-000627-20: A Study to Assess the Efficacy and Safety of FORE8394 in Participants With Cancer Harboring BRAF Alterations

Recruiting
2
250
Europe, Canada, US, RoW
Plixorafenib, FORE8394, PLX8394, Cobicistat, TYBOST(R)
Fore Biotherapeutics, Fore Biotherapeutics
Cancer Harboring BRAF Alterations, HGG, LGG, Solid Tumors, Melanoma BRAF V600E/K Mutated, Thyroid Cancer
06/26
12/26
NCT05174650 / 2020-004938-38: Treatment of Atezolizumab and Derazantinib in Patients With Advanced iCCA With FGFR2 Fusions/Rearrangements

Active, not recruiting
2
27
Europe
Atezolizumab, Tecentriq, Derazantinib, ARQ 087
Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest, ROCHE Pharma AG, Basilea Pharmaceutica International Ltd.
Intrahepatic Cholangiocarcinoma
12/25
08/26
FRACTION, NCT05393674: Fedratinib in Combination with Nivolumab

Active, not recruiting
2
30
Europe
Fedratinib Oral Capsule [Inrebic], Nivolumab
Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest, Prof. F. Heidel, MH Hannover, Celgene International II S.á.r.l.
Primary Myelofibrosis, Secondary Myelofibrosis
12/25
06/26
EXPAND-1, NCT06470763: A Study Evaluating ANV600 Single Agent or in Combination with Pembrolizumab in Participants with Advanced Solid Tumors

Recruiting
1/2
240
Europe, US
ANV600, ANV600 + pembrolizumab (KEYTRUDA®)
Anaveon AG, Merck Sharp & Dohme LLC
Advanced Solid Tumor
10/27
02/28
NeoART, NCT06731803: Platform Trial Evaluating Treatment of Neoadjuvant Trastuzumab-deruxtecan Containing Combination Therapies for HER2+, Resectable Esophagogastric Adenocarcinoma

Recruiting
1/2
36
Europe
Trastuzumab deruxtecan + 5FU/LV, Trastuzumab deruxtecan + FLO
Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest, Daiichi Sankyo
Esophagogastric Adenocarcinoma
12/27
12/27
INSIGHT, NCT03252938: Feasibility and Safety of IMP321 (eftilagimod Alpha) for Advanced Stage Solid Tumors

Hourglass Jan 2021 - Dec 2021 : Final data from INSIGHT-004 study in combination with Bavencio for solid tumors
Checkmark Presentation of data from INSIGHT-004 study in combination with Bavencio for advanced solid tumors at ASCO 2021
Jun 2021 - Jun 2021: Presentation of data from INSIGHT-004 study in combination with Bavencio for advanced solid tumors at ASCO 2021
Checkmark Data from INSIGHT 004 study in combination with avelumab for advanced solid tumors at ESMO 2020
Sep 2020 - Sep 2020: Data from INSIGHT 004 study in combination with avelumab for advanced solid tumors at ESMO 2020
More
Recruiting
1
110
Europe
IMP321, LAG-3Ig fusion protein, Avelumab
Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest, Immutep S.A.S.
Solid Tumors, Peritoneal Carcinomatosis, NSCLC Adenocarcinoma, Urothelial Carcinoma
09/25
09/25
RE-ExPEL, NCT04517747 / 2020-001075-32: Ramucirumab Plus TAS-102 in Patients With Advanced or Metastatic Gastric Adenocarcinoma or the Gastroesophageal Junction

Completed
N/A
20
Europe
Ramucirumab, Cyramza, TAS 102, Lonsurf
Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest, Lilly Deutschland GmbH
Gastric Adenocarcinoma, Metastatic Adenocarcinoma of the Gastroesophageal Junction
01/22
01/23
NCT05222854: Comprehensive Genomic Profiling Combined With Real Life Data of "The German-Registry of Incidental Gallbladder Carcinoma"

Active, not recruiting
N/A
200
Europe
Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest
Gallbladder Carcinoma
06/24
12/99
PLATON, NCT04484636: - Platform for Analyzing Targetable Tumor Mutations (pilot-study)

Completed
N/A
400
Europe
FoundationOne®CDx and FoundationOne®Liquid
Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest, Roche Pharma AG
Hepatocellular Cancer, Cholangiocarcinoma, Gallbladder Cancer, Pancreatic Cancer, Oesophageal Cancer, Stomach Cancer
08/24
12/24
NCT04896931: New Prospective Expanded German Registry of Incidental Gallbladder Carcinoma (PERSUASION)- a Permanent Platform Including All Kind of Biliary Tract Cancers (BTC)

Recruiting
N/A
200
Europe
Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest
Biliary Tract Cancer, Neoadjuvant, Adjuvant and 1st Line
09/29
09/29
PLATON, NCT05489250: The Network

Active, not recruiting
N/A
1000
Europe
Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest
Hepatocellular Cancer, Cholangiocarcinoma, Gallbladder Cancer, Pancreatic Cancer, Oesophageal Cancer, Stomach Cancer
05/32
05/32
GISAR, NCT04122872: German Interdisciplinary Sarcoma Registry

Recruiting
N/A
9000
Europe
Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest
Sarcoma, Sarcoma,Soft Tissue, Sarcoma of Bone, Carcinosarcoma
01/38
01/38
Bajorat, Kristin
PLATON, NCT04484636: - Platform for Analyzing Targetable Tumor Mutations (pilot-study)

Completed
N/A
400
Europe
FoundationOne®CDx and FoundationOne®Liquid
Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest, Roche Pharma AG
Hepatocellular Cancer, Cholangiocarcinoma, Gallbladder Cancer, Pancreatic Cancer, Oesophageal Cancer, Stomach Cancer
08/24
12/24
PLATON, NCT05489250: The Network

Active, not recruiting
N/A
1000
Europe
Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest
Hepatocellular Cancer, Cholangiocarcinoma, Gallbladder Cancer, Pancreatic Cancer, Oesophageal Cancer, Stomach Cancer
05/32
05/32
Zimmermann, Paul
PLATON, NCT04484636: - Platform for Analyzing Targetable Tumor Mutations (pilot-study)

Completed
N/A
400
Europe
FoundationOne®CDx and FoundationOne®Liquid
Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest, Roche Pharma AG
Hepatocellular Cancer, Cholangiocarcinoma, Gallbladder Cancer, Pancreatic Cancer, Oesophageal Cancer, Stomach Cancer
08/24
12/24
PLATON, NCT05489250: The Network

Active, not recruiting
N/A
1000
Europe
Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest
Hepatocellular Cancer, Cholangiocarcinoma, Gallbladder Cancer, Pancreatic Cancer, Oesophageal Cancer, Stomach Cancer
05/32
05/32
Hamann, Karsten
PLATON, NCT04484636: - Platform for Analyzing Targetable Tumor Mutations (pilot-study)

Completed
N/A
400
Europe
FoundationOne®CDx and FoundationOne®Liquid
Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest, Roche Pharma AG
Hepatocellular Cancer, Cholangiocarcinoma, Gallbladder Cancer, Pancreatic Cancer, Oesophageal Cancer, Stomach Cancer
08/24
12/24
PLATON, NCT05489250: The Network

Active, not recruiting
N/A
1000
Europe
Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest
Hepatocellular Cancer, Cholangiocarcinoma, Gallbladder Cancer, Pancreatic Cancer, Oesophageal Cancer, Stomach Cancer
05/32
05/32
Haas, Siegfried
NCT05008809: Post-resection/Ablation Chemotherapy in Patients With Metastatic Colorectal Cancer (FIRE-9 - PORT / AIO-KRK-0418)

Recruiting
3
507
Europe
mFOLFOX6, Folinic acid, Oxaliplatin, 5-fluorouracil (FU), mFOLFOXIRI, Folinic acid, Oxaliplatin, 5-FU, Irinotecan, FOLFIRI, Folinic acid, 5-FU, CAPOX, Capecitaine, Oxaliplatin
Dominik Paul Modest, German Research Foundation, Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest
Colorectal Cancer
11/27
11/30
INFINITY, NCT04389541: Clinical Research Platform on Decision Making and Clinical Impact of Biomarker-Driven Precision Oncology

Completed
N/A
499
Europe
iOMEDICO AG, Bristol-Myers Squibb, Roche Pharma AG
Advanced Solid Tumors or Hematologic Malignancies
06/23
06/23
PLATON, NCT04484636: - Platform for Analyzing Targetable Tumor Mutations (pilot-study)

Completed
N/A
400
Europe
FoundationOne®CDx and FoundationOne®Liquid
Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest, Roche Pharma AG
Hepatocellular Cancer, Cholangiocarcinoma, Gallbladder Cancer, Pancreatic Cancer, Oesophageal Cancer, Stomach Cancer
08/24
12/24
PLATON, NCT05489250: The Network

Active, not recruiting
N/A
1000
Europe
Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest
Hepatocellular Cancer, Cholangiocarcinoma, Gallbladder Cancer, Pancreatic Cancer, Oesophageal Cancer, Stomach Cancer
05/32
05/32
Bankstahl, Ulli
PLATON, NCT04484636: - Platform for Analyzing Targetable Tumor Mutations (pilot-study)

Completed
N/A
400
Europe
FoundationOne®CDx and FoundationOne®Liquid
Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest, Roche Pharma AG
Hepatocellular Cancer, Cholangiocarcinoma, Gallbladder Cancer, Pancreatic Cancer, Oesophageal Cancer, Stomach Cancer
08/24
12/24
PLATON, NCT05489250: The Network

Active, not recruiting
N/A
1000
Europe
Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest
Hepatocellular Cancer, Cholangiocarcinoma, Gallbladder Cancer, Pancreatic Cancer, Oesophageal Cancer, Stomach Cancer
05/32
05/32
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Pace, Andrea
ACTION, NCT05580562: ONC201 in H3 K27M-mutant Diffuse Glioma Following Radiotherapy (the Study)

Calendar Jan 2026 - Dec 2026: Final data from ACTION trial for newly diagnosed H3 K27M-mutant diffuse glioma
Jan 2025 - Mar 2025: Interim data from ACTION trial for newly diagnosed H3 K27M-mutant diffuse glioma
Recruiting
3
450
Europe, Canada, Japan, US, RoW
Dordaviprone (ONC201), Dordaviprone (ONC201) + Placebo, Placebo
Chimerix
H3 K27M, Glioma
08/26
08/26
RACTAC, NCT04224441: Repurposing Chlorpromazine in the Treatment of Glioblastoma

Recruiting
2
41
Europe
Chlorpromazine Pill, Temozolomide
Marco G Paggi, MD, PhD, Regina Elena Cancer Institute, Carlo Besta Neurological Institute, Istituto Oncologico Veneto IRCCS
Glioblastoma Multiforme, MGMT-Unmethylated Glioblastoma
06/22
12/22
NCT04762069 / 2021-003659-40: A Study of Berubicin in Adult Subjects With Recurrent Glioblastoma Multiforme

Hourglass Jan 2023 - Jun 2023 : Data from trial for glioblastoma
Hourglass Jul 2022 - Dec 2022 : Interim analysis data from trial for glioblastoma in adults
Active, not recruiting
2
210
Europe, US
Berubicin, Berubicin Hydrochloride, Lomustine, Lomustine Capsules, CCNU, CeeNU, Gleostine
CNS Pharmaceuticals, Inc., Worldwide Clinical Trials
Glioblastoma Multiforme, Adult
12/24
03/25
eCAN, NCT06007001: Telerehabilitation and Tele-psychological Support in Cancer Patients JA

Recruiting
N/A
354
Europe, RoW
Telemedicine
Sciensano, European Commission
Cancer
09/24
09/24
SILMET, NCT05689619: SILibinin in NSCLC and BC Patients With Single Brain METastasis

Recruiting
N/A
70
Europe
Silibinin, Sillbrain, Placebo
Azienda Ospedaliera Città della Salute e della Scienza di Torino
Brain Metastases, Adult, Non Small Cell Lung Cancer, Breast Cancer
09/25
09/27
Siegler, Gabriele
RAMTAS, NCT03520946 / 2017-004162-99: RAMucirumab in Combination Wth TAS102 vs. TAS102 Alone in Chemotherapy Refractory Metastatic Colorectal Cancer Patients

Completed
3
430
Europe
Ramucirumab, TAS 102
Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest, Eli Lilly and Company, Trium Analysis Online GmbH
Colorectal Cancer
07/24
07/24
NCT05008809: Post-resection/Ablation Chemotherapy in Patients With Metastatic Colorectal Cancer (FIRE-9 - PORT / AIO-KRK-0418)

Recruiting
3
507
Europe
mFOLFOX6, Folinic acid, Oxaliplatin, 5-fluorouracil (FU), mFOLFOXIRI, Folinic acid, Oxaliplatin, 5-FU, Irinotecan, FOLFIRI, Folinic acid, 5-FU, CAPOX, Capecitaine, Oxaliplatin
Dominik Paul Modest, German Research Foundation, Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest
Colorectal Cancer
11/27
11/30
NeoART, NCT06731803: Platform Trial Evaluating Treatment of Neoadjuvant Trastuzumab-deruxtecan Containing Combination Therapies for HER2+, Resectable Esophagogastric Adenocarcinoma

Recruiting
1/2
36
Europe
Trastuzumab deruxtecan + 5FU/LV, Trastuzumab deruxtecan + FLO
Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest, Daiichi Sankyo
Esophagogastric Adenocarcinoma
12/27
12/27
Götze, Thorsten
COMPASS, NCT03164980: QoL-Comparison Between Trabectedin/PLD and Pt-based Therapy in Patients With Pt-sensitive Recurrent Ovarian Cancer

Terminated
4
89
Europe
Trabectidin (Yondelis)
North Eastern German Society of Gynaecological Oncology, Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest, PharmaMar
Quality of Life, Ovarian Cancer, Recurrent Ovarian Carcinoma
08/23
08/23
NCT04817189 / 2019-004686-41: Oral Akynzeo® Vs Standard of Care in Preventing CINV in High-risk MEC Patients (MyRisk)

Completed
4
414
Europe, RoW
NEPA (300mg netupitant/0.5mg palonosetron), Akynzeo® capsules, Granisetron, 2 mg (oral) or 1 mg (IV) OR Palonosetron, 0.5 mg (oral), 0.25mg (IV) OR Ondansetron, 16 mg (oral) or 8 mg (IV) OR Dolasetron 100 mg (oral) OR Tropisetron 5 mg (oral or IV), 5-HT3 RA, Dexamethasone, 8 mg (oral) or equivalent IV dose, corticosteroid
Helsinn Healthcare SA
Chemotherapy-induced Nausea and Vomiting
07/24
07/24
ABC-HCC, NCT04803994 / 2020-004210-35: The Trial: Atezolizumab Plus Bevacizumab vs. Transarterial Chemoembolization (TACE) in Intermediate-stage HepatoCellular Carcinoma

Recruiting
3
434
Europe, Japan
Atezolizumab, Tecentriq, Bevacizumab, Avastin, TACE, transarterial chemoembolization
Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest, F. Hoffmann-La Roche Ltd
Hepatocellular Carcinoma
07/27
07/27
NCT03948789: Phase III Study of MR-Guided Focused Ultrasound Surgery for the Treatment of Uterine Fibroids Compared to Myomectomy

Active, not recruiting
3
127
Europe
Magnetic Resonance Imaging-controlled high-focussed ultrasound therapy, Myomectomy (laparoscopic or open surgical)
Krankenhaus Nordwest
Uterine Fibroids
09/25
10/25
NCT04246684: Short RT Versus RCT,Followed by Chemo.and Organ Preservation for Interm and High-risk Rectal Cancer Patients

Active, not recruiting
3
702
Europe
Oxaliplatin, 85 mg/m2, Control arm, 5FU; 2400 mg/m2, 5-FU, control arm, 5FU, 250 mg/m2, Experimental arm: 5-FU, 5FU, 2400 mg/m2, experimental arm, Oxaliplatin 50 mg/m2, Experimental arm, Folinic Acid, 400 mg/m2, Folinic Acid, Radiotherapy control, 5x5 Gy: 25 Gy, Capecitabine, 1000 mg/m2, Capecitabine, Oxaliplatin 85 mg/m2, radiotherapy experimental, 30 x 1,8 Gy: 54 Gy, Capecitabine, 825 mg/m2, Oxaliplatin, 130 mg/m2, Oxaliplatin
Prof. Dr. med. Claus Rödel
Rectal Cancer Stage III
09/23
09/28
PREVENT, NCT04447352 / 2017-003832-35: HIPEC + FLOT vs. FLOT Alone in Patients With Gastric Cancer and GEJ

Recruiting
3
200
Europe
5-Fluorouracil, 5-FU, Leucovorin, Calciumfolinat, Oxaliplatin, Docetaxel, Cisplatin
Krankenhaus Nordwest, Deutsche Krebshilfe e.V., Bonn (Germany)
Gastric Cancer, Gastroesophageal Junction Adenocarcinoma
11/26
05/27
NCT05008809: Post-resection/Ablation Chemotherapy in Patients With Metastatic Colorectal Cancer (FIRE-9 - PORT / AIO-KRK-0418)

Recruiting
3
507
Europe
mFOLFOX6, Folinic acid, Oxaliplatin, 5-fluorouracil (FU), mFOLFOXIRI, Folinic acid, Oxaliplatin, 5-FU, Irinotecan, FOLFIRI, Folinic acid, 5-FU, CAPOX, Capecitaine, Oxaliplatin
Dominik Paul Modest, German Research Foundation, Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest
Colorectal Cancer
11/27
11/30
CaboRISE, NCT04522908: Dose Escalation Study of Cabozantinib for Advanced HCC Patients with Preserved Liver Function

Completed
2
40
Europe
Cabozantinib Oral Tablet, CABOMETYX
Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest, Johann Wolfgang Goethe University Hospital, Prof. Dr. med. Trojan
Hepatocellular Carcinoma (HCC), Second Line Treatment
10/24
10/24
PRESTO, NCT05713838: Organ Preservation With Durvalumab-based Immunotherapy in Combination With Chemoradiation as Definitive Therapy for Early Stage Esophageal Adenocarcinoma With Indication for Radical Surgery

Recruiting
2
32
Europe
Durvalumab, IMFINZI, FLOT, mFOLFOX-6, Radiotherapy
Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest
Esophagus Adenocarcinoma
12/25
12/28
ADJUBIL, NCT05239169: Immunotherapy With Durva and Treme With or Without Capecitabine in Adjuvant Treatment for Biliary Tract Cancer

Active, not recruiting
2
40
Europe
Durvalumab, Tremelimumab, Capecitabine
Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest
Biliary Tract Cancer (CCA), Intrahepatic Cholangiocarcinoma, Hilar Cholangiocarcinoma, Distal Cholangiocarcinoma, Gall Bladder Carcinoma
12/24
06/25
NCT06680622: Bemarituzumab in FGFR2b+ Patients with Advanced or Metastatic Adenocarcinoma of the Stomach or Gastroesophageal Junction, Who Failed At Least One Prior Line of Palliative Chemotherapy

Recruiting
2
126
Europe
bemarituzumab, paclitaxel, ramucirumab, bemarituzumab, irinotecan, bemarituzumab, trifluridine/tipiracil
Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest, Amgen, Johannes Gutenberg University Mainz, Technical University of Munich
Metastatic Gastro-esophageal Adenocarcinoma
09/27
03/28
NCT06856837: - IKF/AIO-QUINTIS - Evaluating Fruquintinib in Combination With Tislelizumab in Microsatellite Stable / Proficient Mismatch Repair (MSS/pMMR) Metastatic Colorectal Cancer Without Active Liver Metastases

Not yet recruiting
2
140
Europe
Fruquintinib, Fruzaqla, Tislelizumab, Tevimbra, Trifluridine/tipiracil, Lonsurf, Bevacizumab, Avastin
Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest
Metastatic Colorectal Cancer
12/29
12/29
FUTURE, NCT06722183: Futibatinib in Combination With (Chemo)Immunotherapy in Colorectal Cancer and Other Solid Tumor Entities

Not yet recruiting
2
33
Europe
Futibatinib orally administered, Tislelizumab (i.v. 200mg)
Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest, Universitätsmedizin Mainz, I. Medizinische Klinik, Forschungslabor Prof. Möhler
Colorectal Cancer
09/27
09/27
FORTE, NCT05503797 / 2022-000627-20: A Study to Assess the Efficacy and Safety of FORE8394 in Participants With Cancer Harboring BRAF Alterations

Recruiting
2
250
Europe, Canada, US, RoW
Plixorafenib, FORE8394, PLX8394, Cobicistat, TYBOST(R)
Fore Biotherapeutics, Fore Biotherapeutics
Cancer Harboring BRAF Alterations, HGG, LGG, Solid Tumors, Melanoma BRAF V600E/K Mutated, Thyroid Cancer
06/26
12/26
NCT05174650 / 2020-004938-38: Treatment of Atezolizumab and Derazantinib in Patients With Advanced iCCA With FGFR2 Fusions/Rearrangements

Active, not recruiting
2
27
Europe
Atezolizumab, Tecentriq, Derazantinib, ARQ 087
Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest, ROCHE Pharma AG, Basilea Pharmaceutica International Ltd.
Intrahepatic Cholangiocarcinoma
12/25
08/26
FRACTION, NCT05393674: Fedratinib in Combination with Nivolumab

Active, not recruiting
2
30
Europe
Fedratinib Oral Capsule [Inrebic], Nivolumab
Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest, Prof. F. Heidel, MH Hannover, Celgene International II S.á.r.l.
Primary Myelofibrosis, Secondary Myelofibrosis
12/25
06/26
EXPAND-1, NCT06470763: A Study Evaluating ANV600 Single Agent or in Combination with Pembrolizumab in Participants with Advanced Solid Tumors

Recruiting
1/2
240
Europe, US
ANV600, ANV600 + pembrolizumab (KEYTRUDA®)
Anaveon AG, Merck Sharp & Dohme LLC
Advanced Solid Tumor
10/27
02/28
NeoART, NCT06731803: Platform Trial Evaluating Treatment of Neoadjuvant Trastuzumab-deruxtecan Containing Combination Therapies for HER2+, Resectable Esophagogastric Adenocarcinoma

Recruiting
1/2
36
Europe
Trastuzumab deruxtecan + 5FU/LV, Trastuzumab deruxtecan + FLO
Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest, Daiichi Sankyo
Esophagogastric Adenocarcinoma
12/27
12/27
INSIGHT, NCT03252938: Feasibility and Safety of IMP321 (eftilagimod Alpha) for Advanced Stage Solid Tumors

Hourglass Jan 2021 - Dec 2021 : Final data from INSIGHT-004 study in combination with Bavencio for solid tumors
Checkmark Presentation of data from INSIGHT-004 study in combination with Bavencio for advanced solid tumors at ASCO 2021
Jun 2021 - Jun 2021: Presentation of data from INSIGHT-004 study in combination with Bavencio for advanced solid tumors at ASCO 2021
Checkmark Data from INSIGHT 004 study in combination with avelumab for advanced solid tumors at ESMO 2020
Sep 2020 - Sep 2020: Data from INSIGHT 004 study in combination with avelumab for advanced solid tumors at ESMO 2020
More
Recruiting
1
110
Europe
IMP321, LAG-3Ig fusion protein, Avelumab
Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest, Immutep S.A.S.
Solid Tumors, Peritoneal Carcinomatosis, NSCLC Adenocarcinoma, Urothelial Carcinoma
09/25
09/25
RE-ExPEL, NCT04517747 / 2020-001075-32: Ramucirumab Plus TAS-102 in Patients With Advanced or Metastatic Gastric Adenocarcinoma or the Gastroesophageal Junction

Completed
N/A
20
Europe
Ramucirumab, Cyramza, TAS 102, Lonsurf
Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest, Lilly Deutschland GmbH
Gastric Adenocarcinoma, Metastatic Adenocarcinoma of the Gastroesophageal Junction
01/22
01/23
NCT05222854: Comprehensive Genomic Profiling Combined With Real Life Data of "The German-Registry of Incidental Gallbladder Carcinoma"

Active, not recruiting
N/A
200
Europe
Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest
Gallbladder Carcinoma
06/24
12/99
PLATON, NCT04484636: - Platform for Analyzing Targetable Tumor Mutations (pilot-study)

Completed
N/A
400
Europe
FoundationOne®CDx and FoundationOne®Liquid
Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest, Roche Pharma AG
Hepatocellular Cancer, Cholangiocarcinoma, Gallbladder Cancer, Pancreatic Cancer, Oesophageal Cancer, Stomach Cancer
08/24
12/24
NCT04896931: New Prospective Expanded German Registry of Incidental Gallbladder Carcinoma (PERSUASION)- a Permanent Platform Including All Kind of Biliary Tract Cancers (BTC)

Recruiting
N/A
200
Europe
Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest
Biliary Tract Cancer, Neoadjuvant, Adjuvant and 1st Line
09/29
09/29
PLATON, NCT05489250: The Network

Active, not recruiting
N/A
1000
Europe
Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest
Hepatocellular Cancer, Cholangiocarcinoma, Gallbladder Cancer, Pancreatic Cancer, Oesophageal Cancer, Stomach Cancer
05/32
05/32
GISAR, NCT04122872: German Interdisciplinary Sarcoma Registry

Recruiting
N/A
9000
Europe
Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest
Sarcoma, Sarcoma,Soft Tissue, Sarcoma of Bone, Carcinosarcoma
01/38
01/38
Bajorat, Kristin
PLATON, NCT04484636: - Platform for Analyzing Targetable Tumor Mutations (pilot-study)

Completed
N/A
400
Europe
FoundationOne®CDx and FoundationOne®Liquid
Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest, Roche Pharma AG
Hepatocellular Cancer, Cholangiocarcinoma, Gallbladder Cancer, Pancreatic Cancer, Oesophageal Cancer, Stomach Cancer
08/24
12/24
PLATON, NCT05489250: The Network

Active, not recruiting
N/A
1000
Europe
Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest
Hepatocellular Cancer, Cholangiocarcinoma, Gallbladder Cancer, Pancreatic Cancer, Oesophageal Cancer, Stomach Cancer
05/32
05/32
Zimmermann, Paul
PLATON, NCT04484636: - Platform for Analyzing Targetable Tumor Mutations (pilot-study)

Completed
N/A
400
Europe
FoundationOne®CDx and FoundationOne®Liquid
Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest, Roche Pharma AG
Hepatocellular Cancer, Cholangiocarcinoma, Gallbladder Cancer, Pancreatic Cancer, Oesophageal Cancer, Stomach Cancer
08/24
12/24
PLATON, NCT05489250: The Network

Active, not recruiting
N/A
1000
Europe
Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest
Hepatocellular Cancer, Cholangiocarcinoma, Gallbladder Cancer, Pancreatic Cancer, Oesophageal Cancer, Stomach Cancer
05/32
05/32
Hamann, Karsten
PLATON, NCT04484636: - Platform for Analyzing Targetable Tumor Mutations (pilot-study)

Completed
N/A
400
Europe
FoundationOne®CDx and FoundationOne®Liquid
Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest, Roche Pharma AG
Hepatocellular Cancer, Cholangiocarcinoma, Gallbladder Cancer, Pancreatic Cancer, Oesophageal Cancer, Stomach Cancer
08/24
12/24
PLATON, NCT05489250: The Network

Active, not recruiting
N/A
1000
Europe
Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest
Hepatocellular Cancer, Cholangiocarcinoma, Gallbladder Cancer, Pancreatic Cancer, Oesophageal Cancer, Stomach Cancer
05/32
05/32
Haas, Siegfried
NCT05008809: Post-resection/Ablation Chemotherapy in Patients With Metastatic Colorectal Cancer (FIRE-9 - PORT / AIO-KRK-0418)

Recruiting
3
507
Europe
mFOLFOX6, Folinic acid, Oxaliplatin, 5-fluorouracil (FU), mFOLFOXIRI, Folinic acid, Oxaliplatin, 5-FU, Irinotecan, FOLFIRI, Folinic acid, 5-FU, CAPOX, Capecitaine, Oxaliplatin
Dominik Paul Modest, German Research Foundation, Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest
Colorectal Cancer
11/27
11/30
INFINITY, NCT04389541: Clinical Research Platform on Decision Making and Clinical Impact of Biomarker-Driven Precision Oncology

Completed
N/A
499
Europe
iOMEDICO AG, Bristol-Myers Squibb, Roche Pharma AG
Advanced Solid Tumors or Hematologic Malignancies
06/23
06/23
PLATON, NCT04484636: - Platform for Analyzing Targetable Tumor Mutations (pilot-study)

Completed
N/A
400
Europe
FoundationOne®CDx and FoundationOne®Liquid
Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest, Roche Pharma AG
Hepatocellular Cancer, Cholangiocarcinoma, Gallbladder Cancer, Pancreatic Cancer, Oesophageal Cancer, Stomach Cancer
08/24
12/24
PLATON, NCT05489250: The Network

Active, not recruiting
N/A
1000
Europe
Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest
Hepatocellular Cancer, Cholangiocarcinoma, Gallbladder Cancer, Pancreatic Cancer, Oesophageal Cancer, Stomach Cancer
05/32
05/32
Bankstahl, Ulli
PLATON, NCT04484636: - Platform for Analyzing Targetable Tumor Mutations (pilot-study)

Completed
N/A
400
Europe
FoundationOne®CDx and FoundationOne®Liquid
Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest, Roche Pharma AG
Hepatocellular Cancer, Cholangiocarcinoma, Gallbladder Cancer, Pancreatic Cancer, Oesophageal Cancer, Stomach Cancer
08/24
12/24
PLATON, NCT05489250: The Network

Active, not recruiting
N/A
1000
Europe
Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest
Hepatocellular Cancer, Cholangiocarcinoma, Gallbladder Cancer, Pancreatic Cancer, Oesophageal Cancer, Stomach Cancer
05/32
05/32

Download Options